Latest News

Adults at high risk of melanoma recurrence and spread were able to stay cancer-free with personalized vaccines made with mRNA technology.

In a Phase I clinical trial, an immunotherapy stabilized or reduced tumors in several patients with treatment-resistant recurrent glioblastoma.

Nelson LaMarche, PhD, assistant professor in the Department of Pathology and member of the Yale Cancer Biology Institute and Yale Cancer Center, has been presented with a 2026 Breaking Barriers in Cancer Research Award by the V Foundation for Cancer Research, a top-rated cancer research charity.

Madison Strine, PhD, postdoctoral associate in the laboratory of Liza Konnikova, MD, PhD, was recently named a recipient of the Burroughs Postdoctoral Enrichment Program for her project “Defining how early-life T cells program the developing human intestine.”

A team led by John Tsang, PhD, MMath, Anthony N. Brady Professor of Immunobiology, has been awarded a £4,200,000 grant from the Advanced Research + Invention Agency (ARIA) for a project that aims to decode and engineer coordinated immune responses that rapidly clear viruses in an effort to minimize viral spread and immunopathology.

A Q&A with Alexandra Bayer Wildberger, PhD, a postdoctoral associate in the lab of Kevin O’Connor, PhD, who was selected to receive a 2026 American Brain Foundation Next Generation Research Grant in the area of myasthenia gravis for her project, “Investigating the Role of the Immune System’s First Responders in Myasthenia Gravis.”

Yale’s Kevan Herold was the senior investigator on a clinical trial which showed that the drug teplizumab—recently approved for pediatric patients with Stage III type 1 diabetes—delays the progression of the disease.

Degradation of the immune system’s critical maintenance work could be a target for extending a healthy lifespan.

Gut-homing antibodies provide powerful protection against norovirus, a new Yale study finds, revealing a potential new path for developing vaccines and therapies.